Stock Analiz

Co-Diagnostics, Inc. CODX

Medical/Dental Instruments · IPO 2026 · data as of November 13, 2026

$0.26Market cap $3M
Open the interactive analysis →

Co-Diagnostics, Inc. (CODX) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to September 30, 2026 it had revenue of $858888 and net income of -$47M, a net margin of -5527.6%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -62% a year, a 5-year average ROIC of -63%.

About Co-Diagnostics

Co-Diagnostics is listed in the US and classified in medical/dental instruments, IPO year 2026. Revenue went from $7662 in 2017 to $622489 in 2025, growth of about 73.3% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 27% over three years (dilution for shareholders). It spends 3074% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.2
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1000.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-84.1%
Revenue growth (5 yrs, per year)-61.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1803.6%
ROIC (5-yr avg.)-62.6%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$858888$622489$4M$7M$34M$98M$75M$214974$39911$7662—
Net income-$47M-$47M-$38M-$35M-$14M$37M$42M-$6M-$6M-$7M-$2M
Free cash flow-$27M-$30M-$30M-$23M$5M$40M$27M-$6M-$4M-$3M-$1M
EPS (diluted)$-21.85$-4.41$-4.65$-4.50$-1.69$4.61$5.70$-1.39$-1.87$-2.36$-0.73
Net margin-5527.6%-7533.6%-961.4%-518.7%-41.6%37.5%57.0%-2882.0%-15714.3%-90827.9%—
ROIC—-221.8%-56.5%-44.7%-17.7%27.5%62.4%-268.0%-175.2%-87.3%-18244.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $4.00, 1447% above the current price; targets range from $4.00 to $4.00; the consensus rating is “none”; expected EPS is $-3.10 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Co-Diagnostics pay a dividend?

Not currently.

Is Co-Diagnostics a good stock to buy?

We do not give buy or sell advice. Co-Diagnostics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.